The COVID pandemic has affected biopharma companies disparately

It seems almost ludicrous to consider if the biopharma industry has been hurt by the COVID-19 pandemic.

After all, Pfizer reported 82% operational growth for the first quarter, mostly based on the COVID-19 vaccine it developed with Germany’s BioNTech and its antiviral drug Paxlovid. Pfizer is projecting revenues for the year of $98.0 to $102.0 billion, with $32 billion of it coming from the vaccine and $22 million from Paxlovid. And Moderna probably wouldn’t even have a product on the market if it weren’t for its COVID-19 vaccine. For the first quarter, it reported $6.1 billion in revenue.

But those gains were not across-the-board for the industry. It was noted by the European Pharmaceutical Review how disruptive the first year of the pandemic was to ongoing clinical trials.